ClinicalTrials.gg
RecruitingNCT07944183Updated Nov 18, 2026

The PRECISION Partners Platform (P3) Study

An observational study in Cystic Fibrosis (CF), Chronic Suppurative Lung Disease and Primary Ciliary Dyskinesia (PCD), sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Imperial College London · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
850
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Cystic Fibrosis by Imperial College London — 1 open to participants now, 1 under way, none of them phase 3. Cystic Fibrosis · Imperial College London.

Started
2026
the only one that year
Observational
5 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Cystic Fibrosis by Imperial College London, this one is the only one that started in 2026, is one of 5 observational ones, and was the 10th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 200 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

1 of the 10 studies in Cystic Fibrosis by Imperial College London is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 155 Cystic Fibrosis studies recruiting now, 94 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cystic Fibrosis by Imperial College London, or all of them as a file.
02

Study summary

Infections of the lungs are the most common problem for people with Cystic Fibrosis (CF), but also are significant in people with other lung conditions known generally as chronic suppurative lung diseases (CSLD), which can also cause recurrent chest infections. Some of the most common and severe infections are caused by Pseudomonas aeruginosa (Pa), Staphylococcus aureus (Sa), and Aspergillus fumigatus (Af). It is important to detect these early, in order to treat them and prevent damage to the lungs.

At the moment we rely on sputum culture or cough swabs, however, some people (for example small children or those with less severe disease) are not able to provide sputum, and cough swabs are less accurate. Additionally, although modulators such as Kaftrio and Ivacaftor have had significant positive effects on most people with CF taking them, these people often find they no longer produce sputum, and therefore we are not able to test for infections in the same way we did before. Studies have shown that although some people have fewer infections after starting modulators, they generally don't disappear altogether, and therefore we still need a reliable way to test for them.

Furthermore, we have seen that some people react differently to certain infections, and people with more than one infection simultaneously, also respond differently to these infections.

We would like to find new, reliable, easy and acceptable ways of testing for infections that does not require sputum and are acceptable for patients in order to detect, monitor and treat lung infections early. Additionally, we would like to better understand what causes the differing responses patients have to infections, in order to see if there are new ways we can target treatments.

The study is being undertaken in multiple centres across the UK in order to recruit a larger, more diverse and representative group of participants, than we would be able to achieve from one centre alone.

Read the detailed description

This study contributes towards the Cystic Fibrosis Translational Innovation Hub Network in Lung Health and Infection study: PRECISION (PolymicRobial infECtions: bIomarkerS, dIagnOstics \& mechaNisms).

Given the difficulties obtaining sputum in the current CF climate (for example, young children, those with less-advanced lung disease, and those on highly effective CFTR modulators), there is a need for alternative means for sampling to detect infections of the lower airway. This study will aim to look at such alternatives including breath analysis (exhaled volatiles), exhaled breath condensate, skin secretions, blood, stool, and urine, but will also further investigate the utility of upper airway samples such as saliva, cough swabs, throat swabs, nasal secretions, and gargles, and compare these to the traditional methods of BAL (when clinically available), and spontaneously expectorated and induced sputum.

Furthermore, current analysis of samples depends on culture, with inherent diagnostic delays which in turn can delay or result in inappropriate treatment as well as increasing the potential for cross infection between patients. There is thus a need for other options to microbial culture, for example PCR, genomics, transcriptomics and 16s gene sequencing, identification of metabolomic and proteomic biomarkers for infection using mass spectrometry and medical detection dogs, all of which have shown promise previously.

Finding reliable alternatives to sputum may also aid in future clinical trial development; currently protocols often require sputum, and thus are limited to patients who can expectorate. Such alternatives may remove this barrier, allowing these patients to benefit from such trials, but also widening the pool of recruitment, having a more accurate representation of the CF community, and thus having more reliable results.

Finally, there is a need to understand the polymicrobial nature of the CF airway, and the impacts different pathogens have on each other or the commensals (in terms of limiting or exacerbating pathogenicity, or encouraging resistance), and on the host. Sample acquisition, and outcomes from this study, will aid the research of other workstreams within the PRECISION group in developing this understanding, which may allow the identification of biomarkers for risk stratification, or targets for future drug development.

Collaboration between multiple sites throughout the UK will result in access to a larger bank of tissue samples, and differing expertise. This will enable an extremely wide breadth of data, impossible to obtain from a single centre alone, to allow us to effectively answer these questions.

03

Conditions studied

  • Cystic Fibrosis (CF)
  • Chronic Suppurative Lung Disease
  • Primary Ciliary Dyskinesia (PCD)
  • Bronchiectasis
  • Healthy
  • Paediatric and Adult Patients

Keywords

  • Cystic Fibrosis
  • Infection
  • Chronic suppurative lung disease
  • CSLD
  • CF
  • Healthy control
  • Pseudomonas aeruginosa
  • Aspergillus fumigatus
  • Primary Ciliary Dyskinesia
  • PCD
  • Polymicrobial infections
  • Sputum
  • Paediatrics and adult patients
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Males and females with CF, other forms of chronic suppurative lung disease (CSLD) and healthy controls (HC). Selection of patients will be based on their previous clinical microbial culture results.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For patients with CF, diagnosis confirmed by standard criteria.
  • For patients with other forms of CSLD, a clinical diagnosis of either bronchiectasis (CT scan) or PCD (conventional criteria) will have been confirmed.
  • Healthy volunteers will be colleagues and staff contacts (including children) at a participating centre i.e. Royal Brompton Hospital, or will be friends, family or contacts of patients.
  • Ability to perform written (adults only).

Exclusion criteria

Exclusion Criteria:

  • Asthma, or any other chronic respiratory disease (only applicable to healthy controls).
  • Upper or lower respiratory tract infection symptoms within the previous 4 weeks (applicable only to healthy controls).
  • Current smoker/vaper, or ex-smoker/ vaper within the last 10 years (applicable to healthy controls only).
  • Inability to understand or cooperate with the test(s)
  • Inability to give , or withdrawal of informed consent (adults only)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
850 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • People with Cystic Fibrosis (pwCF)

    500 people with Cystic Fibrosis (pwCF)

  • People with chronic suppurative lung disease (CSLD)

    Up to 100 patients with Chronic suppurative lung disease (CSLD)

  • Healthy control

    250 Healthy controls without CF, CSLD or other chronic respiratory disease

06

What researchers measure

Primary outcomes

  1. Exploratory outcomes

    Participants will provide at least one of the following samples which will be analysed by culture to determine infection status as per the current gold standards for diagnosis: 1. Bronchoalveolar lavage (only if being performed for clinical reasons) 2. Spontaneous sputum 3. Induced sputum The following other samples will be offered to participants (who may choose to perform some, or all, depending on preference): 1. Endobronchial biopsy (only collected if being performed clinically) 2. Nasal secretions 3. Saliva 4. Throat swabs 5. Cough swabs 6. Gargles 7. Breath 8. Skin secretions 9. Urine 10. Blood (only collected if being performed clinically in children) The results of these analyses will be combined with the gold standard culture results to determine their ability to identify the infection status of that particular individual. The sensitivity and specificity of these sample types and detection techniques to identify particular infections will then be calculated and compared.

    Time frame: From enrollment to year 5

Secondary outcomes

  1. Utilising the results of the analyses from the primary outcome

    The results of the analyses from the primary outcome will also be used to better understand the polymicrobial interactions in the Cystic Fibrosis lung, for example, competition between microbes, the changing of one microbe's behaviour in response to another, or protection from host defences, and the impact on health.

    Time frame: Enrollment to year 5

07

Study locations

1 of 1 sites recruiting
  • Royal Brompton Hospital, part of Guy's and St Thomas' NHS Foundation Trust
    London, SW3 6LL, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Collaboration between multiple sites throughout the UK will result in access to a larger bank of tissue samples, and differing expertise. This will enable an extremely wide breadth of data, impossible to obtain from a single centre alone, to allow us to effectively answer these questions.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944183
Collaborators
National Heart and Lung Institute, Cardiff University, University of Nottingham, Newcastle University, Queen Elizabeth University Hospital Glasgow, Medical Detection Dogs, University of Amsterdam
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jun 23, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Gina Rivellini
Contact
g.rivellini@imperial.ac.uk
02075947986
Maddy Grassy
Contact
z.grassy@imperial.ac.uk
02075947226
Jane Davies, MBChB, mRcP, MRCPCH, MD
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion